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JA(XI~' Fchmar~ lqqX .~II~'IRA(~I~ I',,~I¢= fil?t 
platolot inhibition m patients with acuto coronary ischomtc .~yn~romos un- 
dergoing angioplO.~ty RESTORE demonstrated a 30% .sk ,,e.Juu,on in the 
composite ondpoint el dosth, MI and repeat procedures (p = 0016) at 7 days 
and at 30 days (p = 0052) To proioct the chnicaL resource and cost linitml 
and 30 day) b~nohts ot~.~orved *n RESTORE to the eat!to US population 
(USP), the N~tmnal Hospital Discharge Sun/cry (NHDS) was utilized to i~m 
tifi~l a coheff of patients m~tm9 RESTORE eligibility cntetia NHDS PTCA 
o~timato5 for the US population for 1994 were approximately 404,000 Mor* 
bidity arxt rosou~e utilization rato~ fron~ RESTORE were applied to t~, USP 
PTCA estimates ~0 determine the ipop~!~tmn incremental bene~ fits of tirotiban 
therapy compafl~l to placebo An estimated reductmn ot approximately 64fi4 
Ml's ~nd 7;~72 emo~loncy repeat a~ast ies  would at~o be avoided at Day 
7, A ¢ommensmat~ f~g,~ion of $17,5,7 Million in inqiat hospit~li~RtJen Costs 
and $787 I~ MIIIio~ in overall costs, excluding drug procurement co,st, wogt~ 
bo eq~'Cled wlth tirofiban therapy Tlmfib~n confem the afqrcmentio~ c!in. 
ieal ~dvanta~ ~llh substanba! CoSt offsets du.ng the initial ho~p~ta!ization 
and 30 d~ys POSt hospitaliz~tmn 
• COII~!fect!ven~Is Ab¢iximab Coronary Of After 
S! .efil!ng: A Oe¢ls!on-analYlt~ Model 
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B~ckgrou~. Abclxim¢Ib (AB) h~,s been shown tO mlprove ~ar~omes aMer 
bottoon angtopias~/but a  an increased cost Whether ~ts bet~hls ~pply aflef 
corc ~an~ tentmg (CS) ana at what co~ ~s not known 
Mortals Wo Oovoloped a ~I  to predict 1he co~Peflect~vene~s (CEi ot 
A['t u~e tn planned CS Baseh~ assumpl=on~ were d~fw¢~ from pubii~heCl 
¢t~la, ana included the annual probab~hly ot cafdra¢ Oeath for pts ~ cor~ 
~/d~so~se (range 0.6%~'9% depending on anatomy, LV f~ncbo~a and 
d~abetes): the ml~tiv~ rlsk (RR) of c~diac motla!ify ~ to pen~proc~ral 
CK el~vation (6% incma~ per 14otd rico in the fat~o Of ~k  CKtnOn~l) 
anq the RR o! p~ri.pt~oceduml CK elevation with AB (0,48). Th@ ~! .  
ity Ot pee@ro~edurat CK elevation (PCK) in pts undergoing C$ (10%) was 
bas~i on d~la from the Steel AntHhmmbot~ R~n St~fy (STAR~), We 
~s~ an AB cost Ot $!,400 and tha; perPproc~raI CK elevation wos~d 
affect cart~zte mort~!lity for 5 years. 
Resut~: The bafseline anatysis for a 60 year ~ n~n six,wed a CE tat'to 
el $6~0,000 Ip~r Y~r O! life= saved (YOLS) for low Osk pts (1.vessel dif=ease. 
no diabeles, normal election fraction) and of $1 fiT,OOO/YOLS for h~gh risk pts 
(mqlt~vessel d~sease, diat)etes, and low election trac1~on)~ Sens~tivOy aealy~is 
showed that malqr determinants Of C[~ were the cost of AB and pCK At a 
~p~ndtng threshold of $50,OGO,~'OLS, AB would be preteffed =n hi(]h ask pts 
d pCK was 35% or ~f it Cost ::.~100 For low ask pts, a~chlevement of a 
tavoml3le CE raho required t?oth a pCK 35% and a net AB cost $400 
Conctu~n The use of AB adtun~'Irvo t CS does net appear COSt-effec. 
t=vO ~n rousne use. Achievement ot CE rat~os comps.able tO other medical 
prast~ces ~equ=res target:ng Of pts at h~gh ns~ tot i3;e cardiac events and 
pen-p~oce~tufal CK elevations 
